Brind.
  1. The European Society of Cardiology Congress was held in Madrid, Spain.

Tenaya Therapeutics presented interim data from the MyClimb study at the European Society of Cardiology Congress.

2 reports, 1 independent Updated Aug 31
Gone quiet
Reports
2
Developments
2
Repetition
0%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Tenaya Therapeutics presented interim data from the MyClimb study at the European Society of Cardiology Congress.

How it developed

Newest first. Tap a step to see who reported it.
  1. Tenaya Therapeutics presented MyClimb study data at the ESC Congress.1 source
  2. Tenaya Therapeutics' trials for TN-201 and TN-401 were cleared by DSMB for continuation.1 source

Keep exploring

Part of

The European Society of Cardiology Congress was held in Madrid, Spain.

Also in this story

All 4 developments

Coverage

Newest first; wire copies grouped
  • GlobeNewswireTenaya Therapeutics Presents Interim Data from MyClimb™ Natural History Study of MYBPC3-associated HCM Pediatric Patients at European Society of Cardiology Congress 2025 Largest Noninterventional Nat
  • GlobeNewswireTenaya Receives Positive Safety Reviews from Independent DSMBs to Advance Both TN-201 and TN-401 Gene Therapy Clinical Trials as Designed Enrollment in Both Dose Cohorts of the MyPEAK™-1 Phase 1b/2 C